Your browser doesn't support javascript.
loading
COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.
Abdorahimi, Mahsa; Pakdel, Farzad; Salehi, Mohammadreza; Alcazar-Fuoli, Laura; Hashemi, Seyed Jamal; Daie Ghazvini, Roshanak; Ahmadkhani, Fardin; Ahmadikia, Kazem; Abdollahi, Alireza; Debran, Juan Carlos Soto; Tabari, Azin; Farrokh, Fatemeh; Mousavand, Atefeh; Afarinesh Khaki, Pegah; Salami Khaneshan, Arezoo; Ibrahim, Ashraf S; Khodavaisy, Sadegh.
Afiliación
  • Abdorahimi M; Department of Microbiology, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran.
  • Pakdel F; Department of Oculo-Facial Plastic Surgery, Department of Ophthalmology, Farabi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Salehi M; Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. salehi.mohamad3@gmail.com.
  • Alcazar-Fuoli L; Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
  • Hashemi SJ; Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Daie Ghazvini R; Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Ahmadkhani F; Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Ahmadikia K; Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Abdollahi A; Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Debran JCS; Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
  • Tabari A; Otorhinolaryngology Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Farrokh F; Otorhinolaryngology Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Mousavand A; Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Afarinesh Khaki P; Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Salami Khaneshan A; Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Ibrahim AS; Institute for Infection and Immunity, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
  • Khodavaisy S; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Mycopathologia ; 188(5): 783-792, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37672164
ABSTRACT

BACKGROUND:

Despite the unprecedented surge in the incidence of mucormycosis in the COVID-19 era, the antifungal susceptibility patterns (ASPs) of COVID-19 associated mucormycosis (CAM) isolates have not been investigated so far and it is unclear if the high mortality rate associated with CAM is driven by decreased susceptibility of Mucorales to antifungal drugs.

OBJECTIVES:

To describe the clinical, mycological, outcome and in vitro ASPs of CAM cases and their etiologies from Iran. PATIENTS/

METHODS:

A prospective study from January 2020 to January 2022 at a referral tertiary hospital in Tehran, Iran was conducted for screening mucormycosis through histopathology and mycological methods. The identity of Mucorales isolates was revealed with ITS-panfungal PCR& sequencing and MALDI-TOF. The AS for amphotericin B, itraconazole, isavuconazole and posaconazole was cleared according to the EUCAST antifungal susceptibility testing protocol.

RESULT:

A total of 150 individuals were diagnosed with CAM. Males constituted 60.7% of the population. The mean age was 54.9 years. Diabetes was the leading risk factor (74.7%). The median interval between diagnosis of COVID-19 and CAM was 31 days. The recovery rate of culture was as low as 41.3% with Rhizopus arrhizus being identified as the dominant (60; 96.7%) agent. Amphotericin B (MIC50 = 0.5 µg/ml) demonstrated the highest potency against Mucorales.

CONCLUSION:

Majority of the cases had either diabetes, history of corticosteroid therapy or simultaneously both conditions. Accordingly, close monitoring of blood glucose should be considered. The indications for corticosteroids therapy are recommended to be optimized. Also, an anti Mucorales prophylaxis may be necessitated to be administrated in high risk individuals. Although amphotericin B was the most active agent, a higher rate of resistance to this antifungal was noted here in comparison with earlier studies on mucormycetes from non-CAM cases.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / COVID-19 / Mucorales / Mucormicosis Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Mycopathologia Año: 2023 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / COVID-19 / Mucorales / Mucormicosis Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Mycopathologia Año: 2023 Tipo del documento: Article País de afiliación: Irán